<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621136</url>
  </required_header>
  <id_info>
    <org_study_id>CTR180-01</org_study_id>
    <nct_id>NCT04621136</nct_id>
  </id_info>
  <brief_title>PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity</brief_title>
  <official_title>PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyushu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyushu University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm phase I/II trial to evaluate the safety and efficacy of&#xD;
      Rho-associated protein kinase(ROCK) inhibitor Ripasudil eye drops for preterm infants with&#xD;
      Retinopathy of Prematurity(ROP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ripasudil eye drops will be administrated to all enrolled preterm infants with zone I/II&#xD;
      stage 1 or greater ROP （except for aggressive posterior ROP, Type1 ROP ）.&#xD;
&#xD;
      The safety and efficacy of ripasudil in treated patients will be assessed in comparison to a&#xD;
      historical control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Adverse Events(AEs) and Adverse Drug Reactions(ADRs)</measure>
    <time_frame>throughout the study duration(up to week16)</time_frame>
    <description>Safety Assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients whose ROP worsens to Type1 ROP in one or both eyes</measure>
    <time_frame>week12 of treatment</time_frame>
    <description>Efficacy Assessment： ripasudil-treated patients will be assessed in comparison to the medical records of a historical control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ROP remission in both eyes</measure>
    <time_frame>week12 of treatment</time_frame>
    <description>Efficacy Assessment： ripasudil-treated patients will be assessed in comparison to the medical records of a historical control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of ripasudil and its metabolite M1</measure>
    <time_frame>throughout the study duration(up to week12)</time_frame>
    <description>Pharmacokinetics, the population pharmacokinetic(popPK)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <arm_group>
    <arm_group_label>Ripasudil eye drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ripasudil eye drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ripasudil ophthalmic solution 0.4%</intervention_name>
    <description>Phase1 A total of three infants will receive ripasudil eye drops(0.4%) once daily for one week, followed by twice-daily drug administration for two weeks. The three infants who participate in Phase1 can continue to receive the eye drop treatment for additional 9 weeks(12 weeks in total)if the investigators determine that there are no safety issues with ripasudil. In addition, a data and safety monitoring board(DSMB)will be held two times to decide whether the new patients can be enrolled into phase1, and also if phase2 can begin.&#xD;
Phase2:A total of 21 patients will receive ripasudil eye drops(0.4%)twice daily for 12 weeks.</description>
    <arm_group_label>Ripasudil eye drops</arm_group_label>
    <other_name>GLANATEC ophthalmic solution 0.4%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Informed consent signed by parents or legal guardians of the patient&#xD;
&#xD;
          -  2. Patients born with less than or equal to 32 weeks of gestational age and/or less&#xD;
             than or equal to 1,500 grams of birth weight&#xD;
&#xD;
          -  3. Patients with the following types of ROP in both eyes&#xD;
&#xD;
               1. Zone I ROP with stage greater than or equal to 1&#xD;
&#xD;
               2. Zone II ROP with stage greater than or equal to 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients with aggressive posterior ROP in one or both eyes&#xD;
&#xD;
          -  2. Patients with type 1 ROP in one or both eyes&#xD;
&#xD;
          -  3. Patients with a confirmed or suspected chromosomal abnormality or genetic disorder&#xD;
&#xD;
          -  4. History of hypersensitivity to ripasudil (including drugs with similar chemical&#xD;
             structure) in patients or their mothers&#xD;
&#xD;
          -  5. Patients or their mothers have participated in another intervention study and have&#xD;
             used the study drug of another intervention study within 30 days prior to enrollment&#xD;
             in this study or within 5 times the half-life of the study drug&#xD;
&#xD;
          -  6. Patients with an ocular structural abnormality that can affect the evaluation of&#xD;
             this clinical study by investigators&#xD;
&#xD;
          -  7. Patients with a clinically significant neurological disease (e.g., intraventricular&#xD;
             hemorrhage grade 3 or higher, severe hydrocephalus with significantly increased&#xD;
             intracranial pressure)&#xD;
&#xD;
          -  8. Patients with inadequate blood access&#xD;
&#xD;
          -  9. Patients with complications, allergies, or worsening systemic conditions that make&#xD;
             it difficult to conduct this trial&#xD;
&#xD;
          -  10. Patients judged unsuitable by investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsuru Arima, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyushu University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akiko Misumi, MPharm</last_name>
    <phone>+81-92-642-5110</phone>
    <email>misumi.akiko.652@m.kyushu-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mitsuru Arima, MD,PhD</last_name>
    <phone>+81-92-642-4802</phone>
    <email>m-arima@eye.med.kyushu-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Occupational and Environmental Health</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>807-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroyuki Kondo, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-850</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuhiro Kimura, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akiko Misumi, MPharm</last_name>
      <phone>+81-92-642-5110</phone>
      <email>misumi.akiko.652@m.kyushu-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Mitsuru Arima, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Yamaguchi M, Nakao S, Arita R, Kaizu Y, Arima M, Zhou Y, Kita T, Yoshida S, Kimura K, Isobe T, Kaneko Y, Sonoda KH, Ishibashi T. Vascular Normalization by ROCK Inhibitor: Therapeutic Potential of Ripasudil (K-115) Eye Drop in Retinal Angiogenesis and Hypoxia. Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):2264-76. doi: 10.1167/iovs.15-17411.</citation>
    <PMID>27124322</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyushu University</investigator_affiliation>
    <investigator_full_name>Mitsuru Arima</investigator_full_name>
    <investigator_title>Center for Clinical and Translational Research</investigator_title>
  </responsible_party>
  <keyword>Retinopathy of Prematurity</keyword>
  <keyword>ROP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

